PATRYS Ltd (PAB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, PATRYS Ltd (PAB) has a cash flow conversion efficiency ratio of -2.365x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-1.73 Million ≈ $-1.23 Million USD) by net assets (AU$732.87K ≈ $518.56K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
PATRYS Ltd - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how PATRYS Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read PAB current and long-term liabilities for a breakdown of total debt and financial obligations.
PATRYS Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PATRYS Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Augros Cosmetic Packaging SA
PA:AUGR
|
-0.287x |
|
Iceni Gold Ltd
AU:ICL
|
-0.017x |
|
Silver Elephant Mining Corp
TO:ELEF
|
0.045x |
|
Greenlane Holdings Inc
NASDAQ:GNLN
|
-0.355x |
|
Perrot Duval Holding SA
SW:PEDU
|
0.023x |
|
Khaitan (India) Limited
NSE:KHAITANLTD
|
0.011x |
|
Kanger International Bhd
KLSE:0170
|
-0.041x |
|
Biomind Labs Inc
NEO:BMND
|
0.025x |
Annual Cash Flow Conversion Efficiency for PATRYS Ltd (2008–2025)
The table below shows the annual cash flow conversion efficiency of PATRYS Ltd from 2008 to 2025. For the full company profile with market capitalisation and key ratios, see how much is PATRYS Ltd worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$732.87K ≈ $518.56K |
AU$-1.77 Million ≈ $-1.26 Million |
-2.421x | -362.62% |
| 2024-06-30 | AU$3.47 Million ≈ $2.46 Million |
AU$-1.82 Million ≈ $-1.28 Million |
-0.523x | +38.08% |
| 2023-06-30 | AU$6.84 Million ≈ $4.84 Million |
AU$-5.78 Million ≈ $-4.09 Million |
-0.845x | -30.75% |
| 2022-06-30 | AU$13.43 Million ≈ $9.50 Million |
AU$-8.68 Million ≈ $-6.14 Million |
-0.646x | -100.76% |
| 2021-06-30 | AU$12.04 Million ≈ $8.52 Million |
AU$-3.88 Million ≈ $-2.74 Million |
-0.322x | +37.06% |
| 2020-06-30 | AU$4.88 Million ≈ $3.45 Million |
AU$-2.50 Million ≈ $-1.77 Million |
-0.512x | -2789.46% |
| 2019-06-30 | AU$7.30 Million ≈ $5.16 Million |
AU$-129.19K ≈ $-91.41K |
-0.018x | +93.81% |
| 2018-06-30 | AU$7.29 Million ≈ $5.16 Million |
AU$-2.09 Million ≈ $-1.48 Million |
-0.286x | +40.32% |
| 2017-06-30 | AU$2.66 Million ≈ $1.88 Million |
AU$-1.28 Million ≈ $-903.55K |
-0.480x | -13.93% |
| 2016-06-30 | AU$3.64 Million ≈ $2.57 Million |
AU$-1.53 Million ≈ $-1.08 Million |
-0.421x | +59.39% |
| 2015-06-30 | AU$3.97 Million ≈ $2.81 Million |
AU$-4.11 Million ≈ $-2.91 Million |
-1.036x | -153.21% |
| 2014-06-30 | AU$12.43 Million ≈ $8.80 Million |
AU$-5.09 Million ≈ $-3.60 Million |
-0.409x | -67.78% |
| 2013-06-30 | AU$10.77 Million ≈ $7.62 Million |
AU$-2.63 Million ≈ $-1.86 Million |
-0.244x | +19.13% |
| 2012-06-30 | AU$12.45 Million ≈ $8.81 Million |
AU$-3.75 Million ≈ $-2.66 Million |
-0.302x | +20.56% |
| 2011-06-30 | AU$13.47 Million ≈ $9.53 Million |
AU$-5.11 Million ≈ $-3.62 Million |
-0.380x | +18.00% |
| 2010-06-30 | AU$15.23 Million ≈ $10.78 Million |
AU$-7.05 Million ≈ $-4.99 Million |
-0.463x | -13.05% |
| 2009-06-30 | AU$17.72 Million ≈ $12.54 Million |
AU$-7.26 Million ≈ $-5.14 Million |
-0.410x | -26.26% |
| 2008-06-30 | AU$22.98 Million ≈ $16.26 Million |
AU$-7.45 Million ≈ $-5.27 Million |
-0.324x | -- |
About PATRYS Ltd
Patrys Limited, together with its subsidiaries, develops antibody technologies for the treatment of cancer and NETosis-driven inflammatory diseases. It develops PAT-DX1, a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10; and PAT-DX3 for treating primary and secondary brain cancers, and metastases that are associated wit… Read more